International Clinical Trial: Cetuximab combined with Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC: an Open-label, Randomized, Prospective, Multicenter phase III Trial

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600128985) titled 'Cetuximab combined with Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC: an Open-label, Randomized, Prospective, Multicenter phase III Trial' on July 29.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Fudan University Shanghai Cancer Center

Condition: relapsed/metastatic head and neck squamous cell carcinoma

Intervention: Experimental group:Combination of PD-1 inhibitor and chemotherapy The same dosing regimen was used as for pembrolizumab/finolizumab, albumin-bound paclitaxel and cisplatin in the experimental group. Control group:Combination of CetuximabPD-1 inhibitora...